False-positive Results in Mammographic Screening for Breast Cancer in Europe: a Literature Review and Survey of Service Screening Programmes
Overview
Authors
Affiliations
Objective: To estimate the cumulative risk of a false-positive screening result in European mammographic screening programmes, and examine the rates and procedures of further assessment.
Methods: A literature review was conducted to identify studies of the cumulative risk of a false-positive result in European screening programmes (390,000 women). We then examined aggregate data, cross-sectional information about further assessment procedures among women with positive results in 20 mammographic screening programmes from 17 countries (1.7 million initial screens, 5.9 million subsequent screens), collected by the European Network for Information on Cancer project (EUNICE).
Results: The estimated cumulative risk of a false-positive screening result in women aged 50-69 undergoing 10 biennial screening tests varied from 8% to 21% in the three studies examined (pooled estimate 19.7%). The cumulative risk of an invasive procedure with benign outcome ranged from 1.8% to 6.3% (pooled estimate 2.9%). The risk of undergoing surgical intervention with benign outcome was 0.9% (one study only). From the EUNICE project, the proportions of all screening examinations in the programmes resulting in needle biopsy were 2.2% and 1.1% for initial and subsequent screens, respectively, though the rates differed between countries; the corresponding rates of surgical interventions among women without breast cancer were 0.19% and 0.07%.
Conclusion: The specific investigative procedures following a recall should be considered when examining the cumulative risk of a false-positive screening result. Most women with a positive screening test undergo a non-invasive assessment procedure. Only a small proportion of recalled women undergo needle biopsy, and even fewer undergo surgical intervention.
[Importance of parametric and molecular imaging for therapeutic management of breast cancer].
Hack C, Wetzl M, Schmidt D, Beckmann M Radiologie (Heidelb). 2024; 65(3):154-161.
PMID: 39643699 DOI: 10.1007/s00117-024-01394-x.
Djuric O, Deandrea S, Mantellini P, Sardanelli F, Venturelli F, Montemezzi S Radiol Med. 2024; 129(9):1288-1302.
PMID: 39162938 DOI: 10.1007/s11547-024-01850-7.
Epidemiology of Breast Cancer Mortality in Kazakhstan, trends and Geographic Distribution.
Igissinov N, Toguzbayeva A, Khamidullina Z, Telmanova Z, Bilyalova Z, Kudaibergenova I Asian Pac J Cancer Prev. 2023; 24(10):3361-3371.
PMID: 37898839 PMC: 10770671. DOI: 10.31557/APJCP.2023.24.10.3361.
Nicosia L, Bozzini A, Signorelli G, Palma S, Pesapane F, Frassoni S Healthcare (Basel). 2023; 11(4).
PMID: 36833045 PMC: 9956946. DOI: 10.3390/healthcare11040511.
Cui Z, Kawasaki H, Tsunematsu M, Cui Y, Rahman M, Yamasaki S Curr Oncol. 2023; 30(2):2073-2087.
PMID: 36826122 PMC: 9955860. DOI: 10.3390/curroncol30020161.